Psilocybin Fundamentals
60-70% 5-HT2A occupancy
At therapeutic psilocybin doses, PET imaging shows 60-70% occupancy of 5-HT2A receptors in the cortex, and that occupancy correlates with psychedelic intensity at r=0.75.
Madsen et al., Neuropsychopharmacology, 2019
r=0.75
correlation between 5-HT2A occupancy and psychedelic intensity measured directly by PET imaging (Madsen 2019)
107 nM
psilocin's binding affinity (Ki) at 5-HT2A, compared to greater than 10,000 nM for inactive psilocybin (Nichols 2016)
2023
year Vargas et al. (Science) discovered that intracellular 5-HT2A receptors in the Golgi drive psilocybin's lasting neuroplasticity
Madsen et al., Neuropsychopharmacology, 2019
View as image ↗The clearest proof that the 5-HT2A receptor is psilocybin's critical target comes from a simple blocking experiment. Give an animal a 5-HT2A antagonist (a molecule that occupies the receptor without activating it) before administering psilocybin, and the psychedelic response disappears entirely. Not diminished. Gone.
Erkizia-Santamaría and colleagues confirmed this precisely in 2022: ketanserin, a selective 5-HT2A blocker, eliminated all psychedelic-like behavioral responses to psilocybin in mice.[2] Other serotonin receptors modulate side effects. The 5-HT2A receptor is the switch.
This article covers the quantitative binding data, the occupancy-intensity relationship, what the minor mushroom alkaloids do at the receptor level, and the 2023 Science discovery about why 5-HT2A selectivity matters far more than previously understood.
Psilocybin is a Schedule I controlled substance in the United States. This article covers pharmacology and receptor science for educational purposes.
For the complete pharmacology overview, see How Psilocybin Works: The Complete Pharmacology Guide.
Key Takeaways
- Blocking the 5-HT2A receptor with ketanserin eliminates all psychedelic-like behavioral responses to psilocybin; 5-HT1A and 5-HT2C modulate secondary effects but not the psychedelic core (Erkizia-Santamaría et al., 2022)
- PET imaging in humans confirmed 60-70% 5-HT2A receptor occupancy at therapeutic psilocybin doses (0.2-0.3 mg/kg), with a direct correlation of r=0.75 between occupancy and psychedelic intensity (Madsen et al., 2019)
- Psilocybin itself barely binds 5-HT2A (Ki greater than 10,000 nM); psilocin, its active metabolite, binds at 107 nM, confirming that psilocybin is a prodrug that must be converted before it can act (Nichols, 2016)
- Counter-intuitively, individuals with lower baseline 5-HT2A receptor density tend to have stronger experiences under psilocybin, suggesting receptor availability plays a complex role in response intensity (Stenbæk et al., 2021)
- Aeruginascin, a minor alkaloid in P. cubensis mushrooms, acts as a 5-HT3 antagonist rather than a 5-HT2A agonist, a fundamentally different receptor target (Sherwood et al., 2020)
- Vargas et al. (Science, 2023) discovered that psychedelics promote neuroplasticity by activating intracellular 5-HT2A receptors inside neurons, which serotonin cannot access because it cannot cross the cell membrane
Why Blocking One Receptor Erases the Experience Entirely
Before the quantitative binding data, the most direct evidence for 5-HT2A's role is pharmacological antagonism. If a receptor truly drives an effect, blocking that receptor should eliminate the effect.
This experiment has been run multiple times. Erkizia-Santamaría and colleagues (2022) systematically tested whether 5-HT2A, 5-HT1A, or 5-HT2C receptor blockade affected psilocybin's psychedelic-like effects in mice, using the head-twitch response as the behavioral proxy for psychedelic activity.[2]
Results: ketanserin (5-HT2A antagonist) blocked all psychedelic head-twitch responses. WAY-100635 (5-HT1A antagonist) did not block the psychedelic response but modulated anxiolytic effects. SB 242084 (5-HT2C antagonist) affected thermoregulatory responses. The psychedelic behavioral signature is 5-HT2A-dependent and nothing else in psilocybin's receptor profile substitutes for it.
The foundational pharmacology review by Nichols (2016) in Pharmacological Reviews provides the comprehensive receptor subtype context: serotonergic psychedelics as a class act as partial agonists at 5-HT2A, meaning they activate the receptor at less than the maximal response level while still producing full downstream effects.[3] Partial agonism matters clinically: it's associated with a ceiling on direct receptor activation while still triggering the downstream signaling cascade.
The Occupancy Data: 60-70% Is Enough to Produce Full Psychedelic Effects
Antagonism studies prove 5-HT2A is necessary. Madsen and colleagues (2019) went further and directly quantified the relationship between receptor occupancy and effect intensity in humans using PET imaging.[1]
Using a 5-HT2A-selective PET radioligand, Madsen imaged receptor occupancy in nine participants who received psilocybin at multiple doses. The findings:
- Therapeutic doses (0.2-0.3 mg/kg) achieved 60-70% cortical 5-HT2A receptor occupancy
- PET-measured occupancy correlated with psychedelic experience intensity at r=0.75
- The relationship was dose-proportional within the tested range
The r=0.75 correlation is direct causal evidence in humans, not inferred from blocking experiments or animal models. The more psilocin occupies 5-HT2A receptors, the more intense the psychedelic experience.
The clinical implication: you need substantial but not complete occupancy to produce full psychedelic effects. 60-70% occupancy is not 100%; some receptors remain unoccupied, yet the experience is fully present. This suggests the 5-HT2A response is triggered by a threshold level of occupancy rather than requiring every available receptor to be engaged.
Why Psilocybin Itself Barely Binds: The Prodrug Problem at the Receptor
A common misconception is that psilocybin acts directly at 5-HT2A. It does not. Psilocybin's binding affinity at 5-HT2A is greater than 10,000 nM, essentially pharmacologically inactive at that receptor. The active molecule is psilocin, psilocybin's dephosphorylated metabolite, which binds at approximately 107 nM.[3]
This distinction is important for understanding receptor selectivity. When researchers describe psilocybin's receptor binding profile, they are almost always describing psilocin's profile. Psilocybin is the stable storage and delivery form; psilocin is the active species at the receptor.
The binding profile in comparison:
| Compound | 5-HT2A Ki | 5-HT2A Activity | Other Notable Binding |
|---|---|---|---|
| Psilocin (active) | ~107 nM | Partial agonist | 5-HT1A, 5-HT2C (secondary) |
| Psilocybin (prodrug) | >10,000 nM | Essentially inactive | Converted to psilocin first |
| Baeocystin (mushroom) | Comparable to psilocin | Active, similar affinity | Lower in vivo potency |
| Aeruginascin (mushroom) | Does not bind 5-HT2A | Not an agonist | 5-HT3 antagonist |
Sources: Nichols 2016, Sherwood et al. 2020, Glatfelter et al. 2022
LSD, for comparison, shares 5-HT2A partial agonism with psilocin but additionally binds dopamine D2 receptors, a binding profile that may explain differences in the character and duration of LSD experiences relative to psilocybin. Psilocin's selectivity for 5-HT2A over dopamine receptors is meaningfully greater than LSD's.
For the deeper story on why the body converts psilocybin to psilocin and what that conversion means for timing and variability, see Psilocybin vs. Psilocin: Understanding the Active Compound.
The Stenbæk Paradox: Why Fewer Receptors Predicts a Stronger Experience
If psilocin's binding affinity at 5-HT2A drives experience intensity, one might expect that people with more 5-HT2A receptors would have stronger experiences. Stenbæk and colleagues (2021) tested this directly in 19 healthy participants using PET imaging to measure baseline 5-HT2A receptor density before psilocybin administration.[4]
The finding was the opposite of the intuitive prediction: lower baseline 5-HT2A receptor binding predicted stronger mystical experience intensity under psilocybin. Participants with fewer available receptors at baseline had more intense experiences.
This paradox has several proposed explanations. One is that people with high baseline receptor density may have chronically higher serotonin activity, making their receptors more desensitized and less responsive to agonist stimulation. Another is that 5-HT2A receptor downregulation represents an adaptation to chronic serotonergic tone; when psilocin arrives and occupies receptors, a brain with fewer but more sensitive receptors may respond more dramatically.
Whatever the mechanism, the Stenbæk finding complicates simple dose-response thinking. Receptor occupancy (Madsen 2019) tells you how many receptors are filled. Baseline receptor density (Stenbæk 2021) tells you how those filled receptors respond. Both matter, and they interact in ways that partly explain why psilocybin's effects are highly variable between individuals at the same dose.
What 5-HT1A and 5-HT2C Actually Do at Therapeutic Doses
5-HT2A is the primary driver of the psychedelic experience, but psilocin also binds other serotonin receptor subtypes. Understanding what those subtypes contribute provides the full picture of receptor selectivity.
Per Erkizia-Santamaría 2022 and the Nichols 2016 review: 5-HT1A binding modulates anxiolytic effects and contributes to the calming dimension of the psilocybin experience.[2][3] Blocking 5-HT1A changes the experiential quality without eliminating the psychedelic core. 5-HT2C binding affects thermoregulation and may contribute to nausea, a common psilocybin side effect.
Neither of these subtypes drives the distinctive perceptual and cognitive effects that define the psychedelic experience. They are secondary modulators in psilocin's pharmacology, relevant to the side effect profile and some subjective qualities, but not the primary mechanism.
The Minor Tryptamines: When Mushroom Alkaloids Target Different Receptors
P. cubensis mushrooms contain more than just psilocybin. Alongside psilocybin and its metabolite psilocin, whole-mushroom preparations contain baeocystin, norbaeocystin, aeruginascin, and related minor tryptamines. Their receptor profiles are not identical to psilocin's.
Sherwood and colleagues (2020) synthesized and tested several of these compounds.[6] Baeocystin demonstrated similar 5-HT2A binding affinity to psilocin, making it an active 5-HT2A agonist, though with lower in vivo potency than the binding data alone would predict. Norbaeocystin showed weaker activity.
The aeruginascin finding is the most structurally unusual: aeruginascin does not act as a 5-HT2A agonist. Instead, it acts as a 5-HT3 antagonist, blocking rather than activating this separate serotonin receptor subtype. Glatfelter and colleagues (2022) found that co-administration of aeruginascin with psilocybin reduced head-twitch responses in mice, consistent with a modulatory rather than additive effect on the psychedelic response.[7]
5-HT3 receptors are Gq-coupled ion channels involved in nausea and gut motility. A 5-HT3 antagonist in this context would resemble the mechanism of antiemetic drugs like ondansetron, potentially explaining why some people report less nausea with whole-mushroom preparations than with equivalent doses of pure synthetic psilocybin.
A 2024 study of minor tryptamines present in P. cubensis found that baeocystin, norbaeocystin, and norpsilocin each showed distinct pharmacological profiles in vivo, suggesting these compounds contribute non-redundantly to the full-mushroom experience rather than simply adding to the psilocybin signal.[8]
The 5-HT2A selectivity picture for whole-mushroom preparations is therefore more complex than for synthetic psilocybin. The primary driver is still psilocin (converted from psilocybin) acting at 5-HT2A. But aeruginascin at 5-HT3 adds an antagonist dimension, and baeocystin adds a second 5-HT2A agonist signal.
The 2023 Discovery That Changed Why 5-HT2A Selectivity Matters
The conventional view of psilocybin pharmacology describes psilocin activating 5-HT2A receptors on the cell surface and triggering downstream signaling. That view is only part of the story.
In 2023, Vargas and colleagues published a paper in Science showing that psychedelics activate a population of 5-HT2A receptors that serotonin cannot reach.[5]
The finding: psilocin is lipid-soluble and crosses the neuronal cell membrane. Inside the neuron, 5-HT2A receptors are expressed not just on the outer surface but in the Golgi apparatus, an organelle deep inside the cell. When psilocin accesses these intracellular receptors, it triggers dendritic spine growth through mTOR and AMPA receptor-dependent signaling pathways. This intracellular activation is the molecular basis for psilocybin's lasting neuroplasticity.
Serotonin cannot reach these receptors. Serotonin is membrane-impermeable: it is released from synapses and binds surface receptors, then is cleared. It never crosses into the cell interior. No matter how much serotonin a synapse contains, it cannot activate the Golgi population of 5-HT2A receptors. SSRIs increase synaptic serotonin availability, but that serotonin still cannot cross the membrane.
This explains a long-standing mystery: why do SSRIs not produce psilocybin-like neuroplasticity? They act on the same serotonin system. The answer is that they can only reach the surface receptors. Psilocin reaches both.
The selectivity of psilocin for 5-HT2A is what makes this access meaningful. A molecule that reached intracellular locations but had broad receptor promiscuity would activate many intracellular targets with unpredictable effects. Psilocin's selectivity for 5-HT2A means the intracellular activation is specific to the same receptor that drives the psychedelic experience at the surface.
For context on how this intracellular plasticity connects to lasting brain changes after a single session, see What Happens in Your Brain on Psilocybin?. And for how 5-HT2A receptor density changes in the days after psilocybin (relevant to tolerance), see Psilocybin Tolerance: How Fast Does It Build?. For a direct comparison with LSD's receptor profile, including its additional D2 binding, see Psilocybin vs. LSD: Similarities and Differences.
The Bottom Line
5-HT2A receptor occupancy is the quantifiable driver of psilocybin's psychedelic effects. At therapeutic doses, psilocin (psilocybin's active metabolite) achieves 60-70% 5-HT2A occupancy, and that occupancy correlates with intensity at r=0.75 (Madsen 2019). Blocking the receptor eliminates the effect entirely (Erkizia-Santamaría 2022). The Stenbæk 2021 paradox shows that fewer baseline receptors predicts stronger experiences, complicating simple dose-response models. In whole-mushroom preparations, aeruginascin acts as a 5-HT3 antagonist rather than a 5-HT2A agonist, potentially modulating nausea. The most significant advance in understanding why 5-HT2A selectivity matters came from Vargas et al. (Science, 2023): psychedelics access intracellular 5-HT2A receptors in the Golgi where serotonin cannot reach, triggering the neuroplasticity cascade responsible for lasting therapeutic effects.
Frequently Asked Questions
Sources & References
- 1. Source details for this reference are not yet available.
- 2. Source details for this reference are not yet available.
- 3. Source details for this reference are not yet available.
- 4. Source details for this reference are not yet available.
- 5. Source details for this reference are not yet available.
- 6. Source details for this reference are not yet available.
- 7. Source details for this reference are not yet available.
- 8. Source details for this reference are not yet available.